Neurocrine, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on the stock and has a $180.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mohit Bansal has given his Buy rating due to a combination of factors that highlight Neurocrine’s promising growth trajectory. The significant increase in patient enrollment for Crenessity, coupled with improved reimbursement coverage, indicates a robust launch and suggests strong commercial execution by the company. This performance is expected to instill confidence among investors regarding Neurocrine’s future growth prospects.
Despite a slight reduction in the midpoint guidance for Ingrezza, the overall sales performance reflects positive impacts from expanded access and increased demand. Although there was a minor decline in Ingrezza’s market share compared to Austedo, the results are still favorable, especially considering Teva’s raised guidance for Austedo. These elements collectively support the Buy rating, as they demonstrate Neurocrine’s ability to navigate challenges and capitalize on growth opportunities.
NBIX’s price has also changed moderately for the past six months – from $153.290 to $136.760, which is a -10.78% drop .